Biocon Q3 Earnings Surge Driven by Biosimilars and Generics

Biocon Q3 Results signal strong momentum for the drugmaker, with solid gains across its Biosimilars and Generics businesses for the quarter ended December 31, 2025.  

The company reported consolidated revenue of Rs. 4,290 crore, up 11%, while operating revenue rose 9% to Rs. 4,173 crore. 

Profit growth outpaced revenue. EBITDA climbed 21% to Rs. 951 crore, delivering a 22% margin. Core EBITDA stood at Rs. 1,221 crore, also up 21%, with margins at 29%. Profit before tax jumped 64% to Rs. 226 crore. Biocon continued to invest in innovation, posting net R&D spending of Rs. 249 crore, or 8% of revenue excluding Syngene. 

Also Read: How Pharma Authentication Tech Enhances ROI and Safety 

Biosimilars, under Biocon Biologics, led the charge with revenue of Rs. 2,497 crore, up 9% year over year. The Generics segment posted Rs. 851 crore, marking a sharp 24% rise, driven by gLiraglutide launches in Europe and stronger performance in the U.S. portfolio. CRDMO arm Syngene contributed Rs. 917 crore, down 3%, impacted by a single large-molecule biologics client. 

Commenting on the Biocon Q3 Results, Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said: “This quarter marks the culmination of several strategic steps that have created a stronger and simpler group structure for Biocon Limited. 

Siddharth Mittal, CEO & MD, Biocon Limited, said: “The Generics business continued to see momentum in the third quarter, delivering strong sequential and year-on-year revenue growth of 10% and 24%, respectively. 

Shreehas Tambe, CEO & MD, Biocon Biologics Limited, added: “Biocon Biologics reported a robust Q3FY26 performance, with EBITDA of ?700 crore, up over 44% year on year, driven by strong demand and favourable pricing across key markets. North America continued to power growth during the quarter."